Amgen Slides After BMO Downgrade and Rival Heart-Drug Miss
BMO cut Amgen to Market Perform on valuation after a 34% YTD rally. A Novartis Lp(a) trial miss also raises questions for Amgen’s olpasiran.
/ 185 items
#XY Analyst Up/Down↓
Canaccord Initiates Belite Bio at Buy With $303 Target on Stargardt Therapy
Canaccord cites tinlarebant as the first drug shown to slow Stargardt lesion growth. The PDUFA date is February 12, 2027.
BTIG Starts Coverage on Tiziana With Buy Rating as Key MS Trial Nears
Nasal foralumab aims to cut brain inflammation in SPMS and MSA ahead of October INFORM-MS data.
William Blair Restarts uniQure Coverage at $73, Sees Path for Huntington’s Gene Therapy
William Blair restarts QURE coverage with a $73 estimate, citing a clearer FDA path for AMT-130 in Huntington’s and cash funding into 2030.
Wall Street Starts Coverage of Latigo as Analysts Back Non-Opioid Pain Pipeline
Four banks initiate coverage of Latigo after its IPO, citing LTG-001, 2027 data, and cash runway into 2028 for non-opioid pain drugs.
Piper Sandler Upgrades Capricor to Overweight, Lifts Target to $25 After FDA Review Extension
Capricor stock jumped after Piper Sandler turned bullish, citing a better risk-reward into the Nov. 22 FDA ruling on its DMD therapy.